Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.850
+0.070 (2.52%)
At close: Mar 27, 2026
Market Cap7.35B +2.7%
Revenue (ttm)763.16M -3.3%
Net Income-175.20M
EPS-0.17
Shares Out1.04B
PE Ration/a
Forward PEn/a
Dividend0.07 (2.39%)
Ex-Dividend Daten/a
Volume1,071,000
Average Volume1,177,350
Open2.790
Previous Close2.780
Day's Range2.790 - 2.880
52-Week Range2.130 - 5.290
Beta0.12
RSI40.14
Earnings DateMar 30, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Sector Healthcare
Founded 1996
Employees 899
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements